Latest Regulatory Filings News

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

Genesis Minerals is set to acquire Magnetic Resources for approximately A$639 million, offering Magnetic shareholders a 25-35% premium. The deal unlocks synergies at the Lady Julie Gold Project, where an updated underground production target extends mine life to 14-19 years with improved economics.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.

EMVision Medical Devices has ramped up recruitment in its pivotal FDA trial across eight hospitals and is nearing results from multiple pre-hospital studies, all while bolstering its cash position with a $3.8 million R&D tax refund and $6.6 million in grant funding.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

WA Kaolin Limited has initiated a partially underwritten pro-rata non-renounceable rights offer to raise up to $34.9 million, aiming to reduce debt, fund plant improvements, and restore working capital amid ongoing ASX suspension.

The Koala Company Limited has issued corrected Appendix 3X notices for directors Daniel Milham and Michael Gordon, clarifying escrow status and relevant interests in securities. This update follows a prior announcement on substantial holder notices and aims to ensure regulatory compliance.

Santana Minerals has finalised the second tranche of its A$130 million capital raising, issuing nearly 19 million shares and securing A$17.04 million before costs. The company confirms ongoing progress towards project construction scheduled for late 2026, supported by strong margins and green hydro power.

De.mem Limited has responded to an ASX query regarding the late lodgement of an Appendix 3Y for director Andreas Hendrik De Wit, attributing the delay to an administrative oversight. The company has outlined existing compliance protocols and introduced additional measures to prevent future lapses.

Eastern Gas Corporation Limited has addressed ASX concerns regarding trading by a non-executive director and a related entity during a closed period, outlining remedial actions and governance reviews.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.